Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies

Journal of Clinical Oncology

Volumn 15, Issue 9, 1997, Pages 3067-3074

  Brown, Randy A ^a   Adkins, D ^a   Goodnough, L T ^a   Haug, J S ^a   Todd, G ^a   Wehde, M ^a   Hendricks, D ^a   Ehlenbeck, C ^a   Laub, L ^a   DiPersio, J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; ALLOGRAFT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RISK; CLINICAL ARTICLE; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HEMATOPOIETIC CELL; HISTOCOMPATIBILITY; HUMAN; LEUKAPHERESIS; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; STEM CELL;

EID: 0030762792     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.9.3067     Document Type: Article

References (42)

1. Horowitz MM: New IBMTR/ABMTR slides summarize current use and outcome of allogeneic and autologous transplants. International Bone Marrow Transplant Registry Newsletter, vol 2, 1995, p 1
2. Weaver CH, Hazelton B, Birch R, et al: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969, 1995
3. Cortelazza S, Viero P, Bellavita P, et al: Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 13:935-941, 1995
4. Spitzer G, Adkins DR, Spencer V, et al: Randomized study of growth factors post-peripheral-blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:661-670, 1994
5. To LB, Roberts MM, Haylock DN, et al: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277-284, 1992
6. Advani R, Chao NJ, Horning SJ, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 116:183-189, 1992
7. Bensinger W, Singer J, Appelbaum F, et al: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158-3163, 1993
8. Broun ER, Gonin R, Kneebone R, et al: A randomized trial of the addition of peripheral blood progenitor cells (PBSC) to autologous bone marrow (ABM) in patients undergoing high dose chemotherapy with autologous progenitor support for breast and germ cell cancer (GCC). Proc Am Soc Clin Oncol 13:433, 1994 (abstr)
9. Smith TJ, Hillner BE, Yanovich S, et al: Economic analysis of peripheral blood progenitor cell (PBSC) or autologous bone marrow (ABM) transplant in relapsed Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL). Proc Am Soc Clin Oncol 14:314, 1995 (abstr)
10. Haas R, Möhle R, Frühauf S, et al: Patients characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-3794, 1994
11. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842-2848, 1995
12. Weaver CH, Buckner CD, Longin K, et al: Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 82:1981-1984, 1993
13. Matsunaga T, Sakamaki S, Kohgo Y, et al: Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 11:103-108, 1993
14. Grigg AP, Roberts AW, Raunow H, et al: Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 86:4437-4445, 1995
15. Lane TA, Law P, Maruyama M, et al: Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 85:275-282, 1995
16. Bensinger WI, Weaver CH, Appelbaum FR, et al: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655-1658, 1995
17. Körbling M, Przepiorka D, Huh YO, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 85:1659-1665, 1995
18. Schmitz N, Dreger P, Suttorp M, et al: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666-1672, 1995
19. Rosenfeld C, Collins R, Pineiro L, et al: Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: A phase II study. J Clin Oncol 14:1314-1319, 1996
20. + hematopoietic stem cells for reconstitution following myeloablative therapy. Cytometry 16:74-79, 1994
21. Haug JS, Todd G, Bremer R, et al: Enhanced sensitivity of CD34 assays for leukapheresis and whole blood. Blood 86:118a, 1995 (suppl 1, abstr 461)
22. dim. Blood 88:402a, 1996 (suppl 1, abstr 1595)
23. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382-1388, 1987
24. Schriber JR, Chao NJ, Long GD, et al: Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 84:1680-1684, 1994
25. Yam PY, Petz LG, Knowiton RG, et al: Use of DNA restriction fragment length polymorphism to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 43:399-407, 1987
26. Ugozzoli L, Yam P, Petz LD, et al: Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 77:1607-1615, 1991
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
28. Nemunaitis J, Rosenfeld CS, Ash R, et al: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 15:949-954, 1995
29. Schriber JR, Chao NJ, Long GD, et al: Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 84:1680-1684, 1994
30. Powles R, Smith C, Milan S, et al: Human recombinant GM- CSF in allogeneic bone-marrow transplantation for leukemia: Double-blind, placebo-controlled trial. Lancet 336:1417-1420, 1990
31. Nemunaitis J, Buckner CD, Applebaum FR, et al: Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 77:2065-2071, 1991
32. Passas-Coelho JL, Braine HG, Davis JM, et al: Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 13:705-714, 1995
33. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555, 1995
34. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 13:1922-1932, 1995
35. Kotasek D, Shepherd KM, Sage RE, et al: Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 9:11-17, 1992
36. Dreger P, Klöss M, Petersen B, et al: Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86:3970-3978, 1995
37. Chatta GS, Price TH, Allen RC, et al: Effects of in-vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84:2923-2929, 1994
38. Malachowski ME, Comenzo RL, Hillyer CD, et al: Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 32:732-735, 1992
39. Roberts AW, Begley CG, Grigg AP, et al: Do steady state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone. Blood 86:2451, 1995 (letter)
40. Link H, Arseniev L, Bahre O, et al: Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood 86:2500-2508, 1995
41. Bacigalupo A, Van Lint MT, Valbonesi M, et al: Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood stem cells in adults with advanced leukemia. Blood 88:353-357, 1996
42. Bensinger WI, Clift R, Martin P, et al: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 88:2794-2800, 1996